Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Till Milde

Showing results (101-110 of 161) with videos related to

Pageof 17
Sort By:
Iscience|January 26, 2026
Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastomaAnna S Kolodziejczak, Florian Selt, Heike Peterziel, et al.
Acta Neuropathologica|December 17, 2015
Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targetsFelix Sahm, Daniel Schrimpf, David T W Jones, et al.
Journal of Neuro-Oncology|April 17, 2024
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokinesDaniela Kocher, Lei Cao, Romain Guiho, et al.
Neuropathology and Applied Neurobiology|December 18, 2020
Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing dataDamian Stichel, Daniel Schrimpf, Philipp Sievers, et al.
Journal of Personalized Medicine|December 23, 2020
Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated <i>ROS1/NTRK</i>-Fusion Positive Pediatric High-Grade GliomaLisa Mayr, Armin S Guntner, Sibylle Madlener, et al.
Science Translational Medicine|January 21, 2021
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastomaRaelene Endersby, Jacqueline Whitehouse, Allison Pribnow, et al.
Acta Neuropathologica|September 18, 2021
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma typesPhilipp Sievers, Damian Stichel, Martin Sill, et al.
JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.
Nature Immunology|September 15, 2025
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade gliomaAugusto Faria Andrade, Romain Sigaud, Evan Puligandla, et al.
Neuro-Oncology|July 26, 2022
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma modelsRomain Sigaud, Lisa Rösch, Charlotte Gatzweiler, et al.
Pageof 17

Showing results (101-110 of 161) with videos related to

Sort By:
Pageof 17
Iscience|January 26, 2026
Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastomaAnna S Kolodziejczak, Florian Selt, Heike Peterziel, et al.
Acta Neuropathologica|December 17, 2015
Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targetsFelix Sahm, Daniel Schrimpf, David T W Jones, et al.
Journal of Neuro-Oncology|April 17, 2024
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokinesDaniela Kocher, Lei Cao, Romain Guiho, et al.
Neuropathology and Applied Neurobiology|December 18, 2020
Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing dataDamian Stichel, Daniel Schrimpf, Philipp Sievers, et al.
Journal of Personalized Medicine|December 23, 2020
Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated <i>ROS1/NTRK</i>-Fusion Positive Pediatric High-Grade GliomaLisa Mayr, Armin S Guntner, Sibylle Madlener, et al.
Science Translational Medicine|January 21, 2021
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastomaRaelene Endersby, Jacqueline Whitehouse, Allison Pribnow, et al.
Acta Neuropathologica|September 18, 2021
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma typesPhilipp Sievers, Damian Stichel, Martin Sill, et al.
JCO Precision Oncology|June 26, 2023
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORMAnna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, et al.
Nature Immunology|September 15, 2025
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade gliomaAugusto Faria Andrade, Romain Sigaud, Evan Puligandla, et al.
Neuro-Oncology|July 26, 2022
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma modelsRomain Sigaud, Lisa Rösch, Charlotte Gatzweiler, et al.
Pageof 17